Therefore, ASO drugs designed to target LUCAT1 can disrupt the LUCAT1‐PTBP1 axis, thereby inhibiting the proliferation of colorectal cancer cells and decreasing cellular resistance to DNA‐damaging drugs [136, 158]. This evidence concerns the gene LUCAT1 and colorectal cancer.